Physician profile
Amarilis Sanchez Valle
NPI 1275841603
$166,146.19
in general payments reported to CMS, 2019-2025
13 companies · $15K in 2025
The $15K reported for 2025 was more than what 89% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $14K · 2021: $26K · 2022: $8,094 · 2023: $38K · 2024: $28K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $35K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Honoraria: $16K · Travel and Lodging: $8,160 · Food and Beverage: $2,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $34,906.68 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,072.00 |
| Honoraria | $15,597.15 |
| Travel and Lodging | $8,160.07 |
| Food and Beverage | $2,408.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $90,000.96 | 2019-2025 | Palynziq |
| Horizon Therapeutics Plc | $29,320.31 | 2020-2023 | Ravicti |
| Ultragenyx Pharmaceutical INC. | $23,951.36 | 2020-2024 | |
| Amgen INC. | $7,374.59 | 2024-2025 | Ravicti |
| Genzyme Corporation | $6,911.02 | 2023 | |
| Alexion Pharmaceuticals, INC. | $4,950.00 | 2019 | |
| Zevra Therapeutics INC | $1,647.15 | 2025 | Olpruva |
| Applied Therapeutics, INC. | $1,125.00 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $793.28 | 2025 | |
| Amicus Therapeutics, INC. | $39.06 | 2019 | |
| Travere Therapeutics, INC. | $33.46 | 2019-2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amarilis Sanchez Valle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.